Computational equilibrium strategies can predict optimal drug combinations to overcome evolutionary trade-offs in antibiotic resistance.
Adversarial Debate Score
66% survival rate under critique
Model Critiques
Supporting Research Papers
- Exploiting evolutionary trade-offs to combat antibiotic resistance
Antibiotic resistance frequently evolves through fitness trade-offs in which the genetic alterations that confer resistance to a drug can also cause growth defects in resistant cells. Here, through ex...
- The Fitness Cost of Antibiotic Resistance: A Critical Factor in Bacterial Adaptation
Antibiotic resistance often incurs fitness costs that can impair bacterial growth, competitiveness, or adaptability in drug-free environments. However, these disadvantages are frequently offset by com...
- Identification of Evolutionary Trade‐Offs Associated With High‐Level Colistin Resistance in Acinetobacter baumannii
Colistin (COL) belongs to the polymyxin group of drugs, which possesses a positive charge and interacts with lipopolysaccharide (LPS) of Gram‐negative bacterial outer membranes. Acinetobacter baumanni...
- Identification of Evolutionary Trade-Offs Associated with High-Level Colistin Resistance in Acinetobacter baumannii
Colistin (COL) belongs to the polymyxin group of drugs which possesses a positive charge and interacts with lipopolysaccharide (LPS) of Gram-negative bacterial outer membrane. Additionally, it can pen...
- Pleotropic Effects of Antibiotic Resistance Mutation
Antibiotic resistance mutations (AMRs) alter the phenotypic (physical) characteristics of an organism, which may result in enhanced fitness under antibiotic stress. However, these mutations often infe...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
Computational equilibrium strategies (specifically evolutionary game theory and Nash equilibrium modeling) can identify drug combinations that exploit collateral sensitivity trade-offs in antibiotic-resistant bacterial populations, such that the predicted combinations achieve ≥2-fold greater reduction in minimum inhibitory concentration (MIC) compared to empirically selected combinations in ≥70% of tested resistant strains, and suppress resistance evolution by ≥50% over 30-day serial passage experiments relative to standard-of-care combinations.
- Computationally predicted combinations achieve <1.2-fold MIC reduction compared to randomly selected combinations in ≥3 independent bacterial species tested.
- Resistance suppression rate of predicted combinations is statistically indistinguishable (p > 0.05, two-tailed t-test) from empirically chosen combinations in serial passage experiments across ≥5 strain replicates.
- Nash equilibrium solutions fail to converge or produce degenerate solutions (all strategies equivalent) in ≥40% of tested drug-pair fitness landscapes.
- Predicted "evolutionarily stable" combinations are overcome by resistance within 15 days in ≥60% of serial passage replicates.
- Model predictions show Pearson correlation r < 0.4 between predicted and observed collateral sensitivity coefficients across a held-out test set of ≥20 drug pairs.
- Independent replication in ≥2 external laboratories fails to reproduce primary findings with effect sizes within 25% of original estimates.
Experimental Protocol
Phase 1 — Computational Model Construction (Days 1–30): Build evolutionary game theory models using empirical fitness landscapes from published collateral sensitivity datasets. Parameterize payoff matrices for pairwise drug interactions. Compute Nash equilibria and evolutionarily stable strategies (ESS) for drug cycling and combination schedules.
Phase 2 — In Vitro Validation (Days 31–90): Test top-5 computationally predicted combinations vs. top-5 empirically selected combinations vs. single-drug controls in E. coli K-12 MG1655 and clinical ESKAPE pathogen isolates (minimum n=3 species, n=6 strains each). Measure MIC, kill curves, and resistance emergence via serial passage (30 days, daily transfer at sub-MIC concentrations).
Phase 3 — Mechanistic Verification (Days 91–120): Whole-genome sequencing of evolved populations at days 0, 10, 20, 30. Quantify mutation frequency, identify resistance mutations, and verify that predicted trade-off loci are under selection as modeled.
Phase 4 — Predictive Generalization (Days 121–150): Apply trained model to 3 novel drug pairs not used in training. Assess prediction accuracy on held-out data. Compute ROC-AUC for binary classification of "effective vs. ineffective" combinations.
- CARD (Comprehensive Antibiotic Resistance Database) v3.2+: resistance gene annotations and mutation data for model parameterization.
- PATRIC/BV-BRC bacterial genomics database: fitness landscape data for ≥500 antibiotic-resistant isolates.
- Collateral sensitivity datasets: Imamovic & Sommer (2013), Lázár et al. (2014), Barbosa et al. (2019) — pairwise MIC matrices for ≥20 antibiotic pairs in E. coli.
- EUCAST/CLSI MIC breakpoint tables for all tested antibiotics.
- PK/PD parameter database (e.g., DrugBank, literature) for 20 candidate antibiotics.
- Experimental fitness landscape: generate in-house checkerboard MIC assays for ≥10 drug pairs × 6 strains = 60 fitness matrices (minimum viable dataset).
- Whole-genome sequencing data: Illumina short-read WGS for evolved populations (estimated 180 samples × 5M reads each).
- Validated game-theory software: EGTtools, Nashpy, or custom Python implementation with unit-tested Nash solver.
- Primary: Predicted combinations achieve ≥2-fold greater MIC reduction vs. empirical combinations in ≥70% of tested strains (p < 0.05, paired t-test, n=18 per group).
- Resistance suppression: ≥50% reduction in resistance emergence rate (Kaplan-Meier log-rank p < 0.01) over 30-day serial passage.
- Model accuracy: Pearson r ≥ 0.65 between predicted and observed collateral sensitivity coefficients on held-out test set (n ≥ 20 drug pairs).
- Generalization: ROC-AUC ≥ 0.75 for synergy prediction on 3 novel held-out drug pairs.
- Mechanistic: ≥80% of resistance mutations in serial passage populations occur at loci predicted by the model's trade-off structure.
- Reproducibility: Effect sizes within 30% of primary estimates when replicated in ≥1 external laboratory.
- MIC fold-change for predicted combinations < 1.2× vs. empirical combinations (below meaningful clinical threshold).
- Resistance emergence rate not significantly different between predicted and comparator combinations (log-rank p > 0.05).
- Model Pearson r < 0.4 on held-out collateral sensitivity data.
- Nash equilibrium solver fails to find unique solutions in >40% of fitness landscapes tested.
- WGS reveals resistance mutations predominantly at loci not captured in model (>60% unexplained mutations).
- Serial passage populations overcome predicted combinations within 10 days in >50% of replicates.
- Computational predictions perform no better than random drug pair selection (ROC-AUC ≤ 0.55).
120
GPU hours
150d
Time to result
$28,000
Min cost
$185,000
Full cost
ROI Projection
- Diagnostics: Companion diagnostic platform to identify patient-specific collateral sensitivity profiles from clinical isolate WGS ($500–2,000 per test; addressable market ~5M resistant infection cases/year in US/EU = $2.5–10B market).
- Software licensing: Equilibrium strategy prediction software licensed to hospital systems and pharmaceutical companies ($50,000–500,000/year per enterprise license; 100 major hospital systems = $5–50M/year recurring revenue).
- Pharmaceutical partnerships: Co-development agreements with antibiotic manufacturers to optimize combination regimens for existing drug portfolios; estimated deal value $10–50M per partnership.
- Biodefense: BARDA/DARPA funding interest for biodefense applications (engineered pathogen resistance management); potential $20–100M in government contracts.
- Veterinary medicine: Agricultural antibiotic resistance management (AMR in livestock is $2B/year problem); adaptation of platform for veterinary use adds significant addressable market.
- Academic licensing: Open-source computational tools with premium support contracts for academic medical centers.
🔓 If proven, this unlocks
Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:
- 1adaptive-drug-cycling-protocols-clinical-implementation
- 2personalized-antibiotic-regimen-optimization-patient-genomics
- 3evolutionary-trap-design-multidrug-resistant-tuberculosis
- 4game-theory-antifungal-combination-resistance-suppression
- 5in-vivo-pharmacodynamic-validation-equilibrium-drug-strategies
Prerequisites
These must be validated before this hypothesis can be confirmed:
- collateral-sensitivity-network-mapping-eskape-pathogens
- evolutionary-game-theory-microbial-fitness-landscape-validation
- antibiotic-resistance-fitness-cost-quantification-clinical-isolates
Implementation Sketch
# Evolutionary Game Theory Drug Combination Optimizer # Architecture Overview ## MODULE 1: Data Ingestion & Preprocessing class CollateralSensitivityLoader: def load_mic_data(sources=["CARD", "PATRIC", "literature_csv"]): # Returns: DataFrame[strain_id, drug_A, drug_B, MIC_A, MIC_B, # MIC_A_after_resistance_to_B, MIC_B_after_resistance_to_A] pass def compute_collateral_coefficient(mic_baseline, mic_after_resistance): # CS_coeff = log2(MIC_after / MIC_baseline) # Negative = collateral sensitivity, Positive = cross-resistance return np.log2(mic_after_resistance / mic_baseline) def build_payoff_matrix(drugs: List[str], strains: List[str]): # Shape: [n_drugs × n_drugs × n_strains] # payoff[i,j,k] = fitness of bacteria resistant to drug_i when exposed to drug_j in strain_k pass ## MODULE 2: Nash Equilibrium Solver class EvolutionaryEquilibriumSolver: def __init__(self, payoff_matrix: np.ndarray): self.payoff = payoff_matrix # [n_strategies × n_strategies] self.game = nashpy.Game(payoff_matrix, -payoff_matrix) # zero-sum approximation def find_nash_equilibria(self): # Use support enumeration for exact solutions equilibria = list(self.game.support_enumeration()) return equilibria # List of (sigma_row, sigma_col) mixed strategy pairs def check_ess(self, strategy: np.ndarray, epsilon=0.01): # ESS condition: f(s,s) > f(s_mutant, s) for all mutants # Returns: bool, stability_score (float) for mutant in self.generate_mutant_strategies(strategy, epsilon): if self.fitness(mutant, strategy) >= self.fitness(strategy, strategy): return False, 0.0 return True, self.compute_stability_margin(strategy) def rank_combinations(self, equilibria): # Score = ESS_stability × collateral_sensitivity_coefficient # Returns: ranked list of drug combinations pass ## MODULE 3: Experimental Design Generator class ExperimentalDesigner: def select_top_combinations(ranked_combinations, n=5): # Returns top-N combinations for wet lab validation pass def generate_checkerboard_layout(drug_A, drug_B, conc_range): # 8×8 96-well plate layout for MIC checkerboard # Returns: plate_map DataFrame pass def design_serial_passage_schedule(combinations, days=30): # Daily transfer protocol with MIC measurement schedule pass ## MODULE 4: Statistical Analysis Pipeline class ValidationAnalyzer: def compute_fici(mic_A_alone, mic_B_alone, mic_A_combo, mic_B_combo): return (mic_A_combo / mic_A_alone) + (mic_B_combo / mic_B_alone) # FICI < 0.5: synergy, 0.5-4.0: indifference, >4.0: antagonism def kaplan_meier_resistance_emergence(time_to_4fold_mic_increase): # Returns: survival curve, log-rank p-value vs. comparator from lifelines import KaplanMeierFitter pass def model_calibration(predicted_cs_coefficients, observed_cs_coefficients): pearson_r, p_value = scipy.stats.pearsonr(predicted, observed) brier_score = sklearn.metrics.brier_score_loss(binary_labels, predicted_probs) return pearson_r, brier_score def roc_analysis(predicted_scores, true_synergy_labels): auc = sklearn.metrics.roc_auc_score(true_synergy_labels, predicted_scores) return auc ## MODULE 5: WGS Analysis Pipeline (Snakemake workflow) # Rule 1: FastQC quality control # Rule 2: BWA-MEM2 alignment to reference genome # Rule 3: GATK HaplotypeCaller variant calling # Rule 4: CARD RGI resistance gene annotation # Rule 5: Compute mutation frequency at predicted trade-off loci # Rule 6: Compare observed vs. predicted resistance mutation spectrum ## MAIN EXECUTION FLOW: if __name__ == "__main__": # 1. Load and preprocess data data = CollateralSensitivityLoader.load_mic_data() payoff_matrices = data.build_payoff_matrix(drugs=DRUG_LIST, strains=STRAIN_LIST) # 2. Solve for equilibria per strain all_predictions = {} for strain in STRAIN_LIST: solver = EvolutionaryEquilibriumSolver(payoff_matrices[:,:,strain]) equilibria = solver.find_nash_equilibria() ess_combinations = [(e, solver.check_ess(e)) for e in equilibria] all_predictions[strain] = solver.rank_combinations(ess_combinations) # 3. Aggregate predictions across strains (consensus ranking) consensus = aggregate_cross_strain_predictions(all_predictions) top5 = ExperimentalDesigner.select_top_combinations(consensus, n=5) # 4. Generate experimental protocols protocols = ExperimentalDesigner.design_serial_passage_schedule(top5) # 5. [WET LAB PHASE - external] # 6. Analyze results results = ValidationAnalyzer.compute_fici(experimental_data) survival = ValidationAnalyzer.kaplan_meier_resistance_emergence(passage_data) calibration = ValidationAnalyzer.model_calibration(predicted, observed) auc = ValidationAnalyzer.roc_analysis(scores, labels) # 7. Report generate_validation_report(results, survival, calibration, auc)
- DAY 7 — Data Quality Check: If <60% of curated MIC data points pass quality filters (CV < 20% across replicates, complete drug-strain coverage), abort and expand data collection before proceeding. Estimated cost saved by early abort: $15,000–40,000.
- DAY 14 — Nash Solver Validation: If Nash equilibrium solver fails to find unique solutions in >40% of synthetic benchmark games (with known analytical solutions), abort computational phase and redesign solver architecture. Cost saved: $10,000–25,000.
- DAY 30 — Model Calibration Pre-check: If Pearson r < 0.35 between model predictions and held-out literature collateral sensitivity values (n=10 drug pairs), abort before wet lab phase. Cost saved: $80,000–150,000.
- DAY 45 — MIC Assay Reproducibility: If coefficient of variation for MIC measurements exceeds 30% across biological replicates in first strain tested, halt wet lab work and troubleshoot assay conditions. Cost saved: $30,000–60,000.
- DAY 60 — Early Serial Passage Signal: If at day 10 of serial passage, resistance emergence rates are statistically indistinguishable between predicted and comparator combinations (p > 0.2, interim analysis), trigger pre-specified futility analysis; abort if futility boundary crossed. Cost saved: $20,000–40,000.
- DAY 90 — WGS Mutation Spectrum Check: If >70% of resistance mutations in evolved populations occur at loci completely absent from model's trade-off structure, abort mechanistic validation phase and revise model assumptions. Cost saved: $15,000–30,000.
- DAY 120 — Generalization Test: If ROC-AUC on held-out drug pairs < 0.55 (not better than chance), abort Phase 4 and report negative result; do not proceed to external replication. Cost saved: $10,000–20,000.